-
公开(公告)号：KR1020110090591A
公开(公告)日：2011-08-10
申请号：KR1020100010465
申请日：2010-02-04
Applicant: 충남대학교산학협력단
IPC: A61K9/127 , A61K9/32 , A61K31/4436 , A61K47/30
CPC classification number: A61K9/1273 , A61K9/1277 , A61K31/4439 , A61K47/22 , A61K47/30 , Y10S514/866
Abstract: PURPOSE: A drug-encapsulated biocompatible polymer micelle is provided to maximize encapsulation of drugs and to improve safety in a solution of the micelle. CONSTITUTION: A biocompatible polymer micelle contains amphiphilic diblock copolymer, hydrotrophic formulation, and insoluble drug. A method for manufacturing the micelle comprises: a step of mixing amphiphilic diblock copolymers and insoluble drug under the presence of a solvent to prepare a gel; a step of dispersing the gel in an aqueous phase and adding hydrotrophic formulation to prepare a micelle solution; and a step of freeze-drying the micelle solution. The insoluble drug is pioglitazone, rosiglitazone, or mixture thereof. A pharmaceutical composition for treating or preventing diabetes contains the micelles as an active ingredient.
Abstract translation: 目的：提供药物包封的生物相容性聚合物胶束，以最大程度地使药物的包封和改善胶束溶液的安全性。 构成：生物相容性聚合物胶束含有两亲性二嵌段共聚物，水合物制剂和不溶性药物。 制造胶束的方法包括：在溶剂存在下混合两亲二嵌段共聚物和不溶性药物以制备凝胶的步骤; 将凝胶分散在水相中并加入营养制剂以制备胶束溶液的步骤; 以及将胶束溶液冷冻干燥的步骤。 不溶性药物是吡格列酮，罗格列酮或其混合物。 用于治疗或预防糖尿病的药物组合物含有胶束作为活性成分。
-
公开(公告)号：KR1020110057796A
公开(公告)日：2011-06-01
申请号：KR1020090114352
申请日：2009-11-25
Applicant: 한국교통대학교산학협력단 , 충남대학교산학협력단 , 이니스트에스티 주식회사
IPC: A61K47/36 , A61K47/12 , A61P35/00 , A61K31/203
CPC classification number: A61K47/61 , A61K31/203 , A61K47/545
Abstract: PURPOSE: A drug delivery system for anticancer and antitumor with ternary biomolecules conjugated with heparin is provided to support and release anticancer or antitumor drugs without side effects. CONSTITUTION: A drug delivery system for anticancer and antitumor contains ternary biomolecules containing heparin, aminized folic acid, and compounds with anticancer or antitumor activities. The heparin is a structure having hydroxy group(-OH), carboxy group(-COOH), and amino group(-NH_2). The compound with anticancer or antitumor activities contains carboxy group(-COOH) or amino group(-NH_2). The compouns is retinoic acid, paclitaxel, doxetaxel, vincristine, or vinorelbine.
Abstract translation: 目的：提供与肝素结合的三元生物分子的抗癌和抗肿瘤药物递送系统，以支持和释放抗癌药或抗肿瘤药物，无副作用。 构成：用于抗癌和抗肿瘤的药物递送系统包含含有肝素，氨基化叶酸和具有抗癌或抗肿瘤活性的化合物的三元生物分子。 肝素是具有羟基（-OH），羧基（-COOH）和氨基（-NH 2）的结构。 具有抗癌或抗肿瘤活性的化合物含有羧基（-COOH）或氨基（-NH 2）。 组合物是视黄酸，紫杉醇，多西他赛，长春新碱或长春瑞滨。
-
公开(公告)号：KR1020100091365A
公开(公告)日：2010-08-19
申请号：KR1020090010522
申请日：2009-02-10
Applicant: 충남대학교산학협력단
Abstract: PURPOSE: A polymer penetration pipe and a manufacturing method thereof are provided to manufacture reactivity, corrosiveness, toxicity material, or moisture reference gas. CONSTITUTION: A polymer penetration pipe includes a raw material for manufacturing reference materials. The inner surface of the penetration pipe includes polymer materials which are reformed to the fluorine. The polymer material includes one among silicon, poly tetra fluro ethylene, polyethylene, polypropylene, polyvinylacetate, polyamide, polyester, polyethylene terephthalate, nylon and their combination.
Abstract translation: 目的：提供聚合物渗透管及其制造方法，以制造反应性，腐蚀性，毒性物质或水分参考气体。 构成：聚合物穿透管包括用于制造参考材料的原料。 穿透管的内表面包括被重整成氟的聚合物材料。 聚合物材料包括硅，聚四氟乙烯，聚乙烯，聚丙烯，聚乙酸乙烯酯，聚酰胺，聚酯，聚对苯二甲酸乙二醇酯，尼龙及其组合中的一种。
-
-
-
Patent Agency Ranking
-
17.发明公开
公开(公告)号：KR1020140146813A
公开(公告)日：2014-12-29
申请号：KR1020130069575
申请日：2013-06-18
Applicant: 충남대학교산학협력단
CPC classification number: C08B37/003 , C08L5/08
Abstract: The present invention relates to glycol chitin derivatives having temperature-sensitive sol-gel transition, method for preparing the same, and a hydrogel prepared by cross linking and, more specifically, to glycol chitin derivatives having sol-gel transition at a specific temperature and including double bond in molecular structure, a method for preparing the same, and a hydrogel prepared by cross linking reaction of double bond of the glycol chitin derivatives. The glycol chitin derivatives and the hydrogel prepared by cross linking the same have excellent biocompatibility to be applied to various fields like the medical field, bio field, electronic field, etc.
Abstract translation: 本发明涉及具有温度敏感的溶胶 - 凝胶转变的二醇几丁质衍生物，其制备方法和通过交联制备的水凝胶，更具体地说涉及在特定温度下具有溶胶 - 凝胶转变的二醇几丁质衍生物，包括 分子结构中的双键，其制备方法和通过二醇几丁质衍生物的双键的交联反应制备的水凝胶。 乙二醇几丁质衍生物和通过其交联制备的水凝胶具有优异的生物相容性，可用于医疗领域，生物领域，电子领域等各个领域。
-
公开(公告)号：KR1020140055257A
公开(公告)日：2014-05-09
申请号：KR1020120121812
申请日：2012-10-31
Applicant: 충남대학교산학협력단
IPC: C08B37/08
CPC classification number: C08B37/003 , C08L5/08
Abstract: The present invention relates to glycol chitosan derivative having hydrophobic substituent, to a method to prepare same and to a use of the same. More specifically, the glycol chitosan derivative of the present invention is configured in that a portion of the amine group in the number 2 position is substituted with an acetyl group and a hydrophobic group. The glycol chitosan derivative has thermo-sensitive characteristics which might cause reversible sol-gel transition at a specific temperature, thereby can widely be applied in the medical field, bio field, electronic field, etc.
Abstract translation: 本发明涉及具有疏水取代基的二醇壳聚糖衍生物，其制备方法及其用途。 更具体地说，本发明的乙二醇壳聚糖衍生物的构成是，2位的胺基的一部分被乙酰基和疏水基取代。 乙二醇壳聚糖衍生物具有可能在特定温度下引起可逆溶胶 - 凝胶转变的热敏特性，可广泛应用于医疗领域，生物领域，电子领域等。
-
公开(公告)号：KR1020130030831A
公开(公告)日：2013-03-28
申请号：KR1020110093908
申请日：2011-09-19
Applicant: 충남대학교산학협력단
CPC classification number: A61K9/146 , A61K31/41 , A61K2121/00 , B82Y5/00
Abstract: PURPOSE: A method for preparing a pranlukast nano solid dispersant is provided to improve solubility and thermodynamic stability and to suppress recrystallization. CONSTITUTION: A method for preparing a pranlukast nano solid dispersant comprises: a step of uniformly mixing 1g of pranlukast, 2-6g of polyethylene glycol, and 0.1-3g of poloxamer surfactant; a step of fusing and drying the mixture; and a step of dissolving the dried material in a solvent and removing the solvent. The pranlukast nano solid dispersant contains pranlukast, polyethylene glycol, and poloxamer. The particle size of the pranlukast nano solid dispersant is 250-350 nm.
Abstract translation: 目的：提供一种制备普鲁诺司特纳米固体分散剂的方法，以提高溶解性和热力学稳定性，抑制再结晶。 构成：制备普鲁司特纳米固体分散剂的方法包括：将1g普罗司他，2-6g聚乙二醇和0.1-3g泊洛沙姆表面活性剂均匀混合的步骤; 融合和干燥混合物的步骤; 以及将干燥的材料溶解在溶剂中并除去溶剂的步骤。 普鲁司特纳米固体分散剂含有普鲁司特，聚乙二醇和泊洛沙姆。 普兰卡斯特纳米固体分散剂的粒径为250-350nm。
-
公开(公告)号：KR1020120020386A
公开(公告)日：2012-03-08
申请号：KR1020100083967
申请日：2010-08-30
Applicant: 충남대학교산학협력단
CPC classification number: C08B37/003 , A61K47/36 , C08L5/08
Abstract: PURPOSE: A glycol chitosan derivative is provided to have improved solubility to organic solvent, to form nanosized self aggregate, and to have thermo-sensitive sol/gel phase transition behavior, thereby using for drug delivery system. CONSTITUTION: A glycol chitosan derivative has a structure of chemical formula 1. In chemical formula 1, n is the integer of 10-10000. The acetylation degree of the glycol chitosan derivative is 20-90%. A manufacturing method of the glycol chitosan derivative in chemical formula 1 comprises a step of acetylation of glycol chitosan in chemical formula 1 to an acetylating agent. The acetylating agent is acetic anhydride. The drug delivery system comprises the chitosan derivative.
Abstract translation: 目的：提供乙二醇壳聚糖衍生物，以改善对有机溶剂的溶解度，形成纳米尺寸的自聚集体，并具有热敏溶胶/凝胶相变行为，从而用于药物输送系统。 构成：乙二醇壳聚糖衍生物具有化学式1的结构。在化学式1中，n为10-10000的整数。 乙二醇壳聚糖衍生物的乙酰化度为20-90％。 化学式1中的乙二醇壳聚糖衍生物的制造方法包括将化学式1中的二醇壳聚糖乙酰化成乙酰化剂的步骤。 乙酰化剂是乙酸酐。 药物递送系统包括壳聚糖衍生物。
-
-
-
-
-
-
-
-
-
Search Results
46
records
(took 0.025 seconds)
